Sign up for Table of Contents Alerts.
Email this page
Print this page
Research Paper
Chimeric toxins inhibit growth of primary oral squamous cell carcinoma cells
Christopher Bachran, Iring Heisler, Diana Bachran, Katrin Dassler, Matthias F. Melzig, Jürgen Ervens and Hendrik Fuchs
volume 7 | issue 2
February 2008Pages: 237 - 242
Subscribe to this journal for $129/year
Treatment of oral squamous cell carcinoma (OSCC) is currently based on surgery and radiotherapy. Prolongation of the survival time of patients with progressing tumors is infrequently achieved. To improve the therapeutic options, targeted therapies are a favorable alternative. Therefore, we analyzed the effect of a chimeric toxin (CT) named SE consisting of the epidermal growth factor and the plant protein toxin saporin from Saponaria officinalis. A second construct (SA2E) additionally contains a peptidic adapter designed to enhance efficacy of the CT in vivo and to reduce side effects. The IC50 values for an oral squamous cell carcinoma cell line (BHY) were 0.27 nM and 0.73 nM for SE and SA2E, respectively, while fibroblasts remained unaffected. To investigate primary tumor cells, we developed a technique to analyze freshly prepared OSCC cells of 28 patients in a stem cell assay directly after surgery. Cells were treated for 1 h with the CTs, subsequently seeded into soft agar and colony growth determined after 12 weeks. In spite of the short time of CT incubation, the amount of colonies was reduced to about 78% by 10 nM and to 69% by 100 nM of either toxin. A combined application of 10 nM SA2E with a saponin from Gypsophila paniculata reduced the amount of surviving cells to 68%. The results demonstrate the impact of the CTs on OSCC cells and depict that the stem cell assay is suitable to determine the potential of anti-tumor drugs before studies in vivo will be initiated.
Authors
Christopher Bachran
Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
Iring Heisler
Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
Diana Bachran
Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
Katrin Dassler
Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
Matthias F. Melzig
Freie Universität Berlin, Berlin, Germany
Jürgen Ervens
Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
Hendrik Fuchs
Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany





